Oracle Cancer Trust

Oracle Cancer Trust Immunotherapy Christmas Appeal

Help fund more research into better, more effective treatments for head and neck cancer that are kinder too. We want more people to survive for longer, so they can take that holiday of a lifetime, enjoy family, take on that bucket list challenge. To thrive and to do the things we can take for granted; eat, drink, speak and swallow with ease and confidence.

Donations open 12:00 PM, 3 December 2019 to 12:00 PM, 10 December 2019


Registered Charity in England and Wales (1142037)

Campaign target


Amount raised




Championed by The Hospital Saturday Fund

  • We're just so thankful you're here, working to help us, people who have had head and neck cancer. I don’t know what will happen in the future, but if the worst happens, I know with things like immunotherapy treatments, you're making sure that I have some options.

    — Carole, Oracle supporter who was treated for head and neck cancer 8 years ago


We need new ways of tackling head and neck cancer. In the UK 62,500 people are living with head and neck cancer. Between 25-65% of people diagnosed will live beyond 5 years. We want to radically improve that. And we want more people to live in good health, without the far-reaching side effects some people experience after treatment, affecting their speech, swallowing, eating or even sight and hearing. As the 6th most common form in the UK, head and neck cancer receives just 2% of funding. With your help we can change that.


Innovative treatments are in development, and immunotherapy is proving very exciting. It’s a way to harness the body's own immune system and hopefully treat hard to reach cancers. With immunotherapy, working alongside other techniques like chemo-radiotherapy and surgery, we hope to improve survival and preserve more of the senses, improving quality of life for people affected by head and neck cancers. We have tantalising studies on the horizon that with your help could be game-changing, revealing tumours to our immune systems, boosting their susceptibility to radiotherapy and targeting treatments.